Effects of telmisartan on renal excretory function in conscious dogs

Journal of International Medical Research

Volumn 29, Issue 2, 2001, Pages 131-139

  Schierok, H ^a   Pairet, M ^a   Hauel, N ^a   Wienen, W ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Creatinine; Diuresis; Potassium; Renal function; Sodium; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CHLORIDE; CREATININE; DRUG VEHICLE; POTASSIUM; SODIUM; TELMISARTAN;

ANIMAL EXPERIMENT; ARTICLE; CHLORIDE URINE LEVEL; CONSCIOUSNESS; CONTROLLED STUDY; CREATININE URINE LEVEL; DIURESIS; DOG; DOSE RESPONSE; FEMALE; KIDNEY FUNCTION; NATRIURESIS; NONHUMAN; POTASSIUM EXCRETION; SODIUM URINE LEVEL; TIME; URINARY EXCRETION; URINE VOLUME;

EID: 0035020690     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000102900210     Document Type: Article

References (20)

1. Chan DP, Sandok EK, Aarhus LL, Heublein DM, Burnett JC, Jr: Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog. Am J Hypertens 1992; 5: 354-360.
2. Harris PJ: Regulation of proximal tubule function by angiotensin. Clin Exp Pharmacol Physiol 1992; 19: 213-222.
3. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PB: Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992; 32: 135-165.
4. Bovee KC, Wong PC, Timmermans PB, Thoolen MJ: Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 1991; 4: 327S-333S.
5. Wong PC, Hart SD, Duncia JV, Timmermans FB: Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol 1991; 202: 323-330.
6. Neutel JM, Smith DHG: Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-217.
7. Wienen W, Hauel N, van Meel JC, Narr B, Ries U, Entzeroth M: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245-252.
8. Wienen W, Entzeroth M: Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR 277 in the rat. J Hypertens 1994; 12: 119-128.
9. Bumier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, et al: Short-term and sustained renal effects fo angiotensin II receptor blockade in healthy subjects. Hypertension 1996; 25: 602-609.
10. Marsden PA, Brennet BM, Bailermann BJ: Mechanisms of angiotensin action on vascular smooth muscle, the adrenal and the kidney. In: Hypertension (Laragh JH, Brenner BM, eds). New York: Raven Press, 1990; pp1247-1271.
11. Timmermans PBWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
12. Sechi LA, Grady EF, Griffin CA, Kalinyak JE, Schambelan M: Distribution of angiotensin II receptor subtypes in rat and human kidney. Am J Physiol 1992; 262: F236-F240.
13. Xie M-H, Liu F-Y, Wong PC, Timmermans PB, Cogan MG: Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist. Kidney Int 1990; 38: 473-479.
14. Clark KL, Robertson MJ, Drew GM: Renal pharmacology of GR138950, a novel nonpeptide angiotensin AT1 receptor antagonist. Eur J Pharmacol 1995; 280: 195-203.
15. Clark KL, Robertson MJ, Drew GM: Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog. Br J Pharmacol 1993; 109: 148-156.
16. Keiser JA, Bjork FA, Hodges JC, Taylor DG, Jr: Renal hemodynamic and excretory responses to PD 123319 and losartan, nonpeptide AT1 and AT2 subtype-specific angiotensin II ligands. J Pharmarol Exp Ther 1992; 263: 1154-1160.
17. Morgan DB, Davidson C: Hypokalaemia and diuretics: an analysis of publications. BMJ 1980; 280: 905-908.
18. Andrén L, Weiner L, Svensson A, Hansson L: Enalapril with either a 'very low' or 'low' dose of hydrochlorothiazide is equally effective in essential hypertension. A double-blind trial in 100 hypertensive patients. J Hypertens 1983; 1 (Suppl 2): 384-386.
19. Skoularigis J, Strugo V, Chopamba A, Setekge S, Sareli P: Low doss hydrochlorothiazide (12.5 to 25 mg daily) as monotheraphy in black patients with mild to moderate hypertension. Assessment by ambulatory blood pressure monitoring. Am J Hypertens 1993; 8: 1046-1050.
20. Bohm M, Lee M, Krentz R, Kim S, Schinke M, Djavidani B, et al: Angiotensin II receptor blockade in TGR(mREN2)27: effects of reninangiotensin-system gene expression and cardiovascular functions. Hypertension 1995; 13: 891-899.